vTv Therapeutics Appoints New CEO & Chairman

Ticker: VTVT · Form: 8-K · Filed: Mar 14, 2024 · CIK: 1641489

Vtv Therapeutics Inc. 8-K Filing Summary
FieldDetail
CompanyVtv Therapeutics Inc. (VTVT)
Form Type8-K
Filed DateMar 14, 2024
Risk Levelmedium
Pages2
Reading Time2 min
Key Dollar Amounts$0.01
Sentimentneutral

Sentiment: neutral

Topics: leadership-change, management-transition

Related Tickers: VTVT

TL;DR

vTv Therapeutics just got a new CEO and Chairman, Dr. Stephen L. Hoffman.

AI Summary

vTv Therapeutics Inc. announced on March 13, 2024, a change in its board of directors. Specifically, Dr. Stephen L. Hoffman has been appointed as the new Chief Executive Officer and Chairman of the Board. This appointment follows the departure of Dr. Michael L. Smith from these roles.

Why It Matters

A change in leadership, especially at the CEO and Chairman level, can signal a shift in company strategy and future direction.

Risk Assessment

Risk Level: medium — Leadership changes can introduce uncertainty regarding future strategy and execution, impacting the company's performance.

Key Players & Entities

  • vTv Therapeutics Inc. (company) — Registrant
  • Dr. Stephen L. Hoffman (person) — Appointed CEO and Chairman of the Board
  • Dr. Michael L. Smith (person) — Departed CEO and Chairman of the Board
  • March 13, 2024 (date) — Date of Report

FAQ

Who has been appointed as the new Chief Executive Officer and Chairman of the Board of vTv Therapeutics Inc.?

Dr. Stephen L. Hoffman has been appointed as the new Chief Executive Officer and Chairman of the Board.

When was this leadership change reported?

This leadership change was reported on March 13, 2024.

Who previously held the positions of CEO and Chairman of the Board?

Dr. Michael L. Smith previously held these positions.

What is the state of incorporation for vTv Therapeutics Inc.?

The state of incorporation for vTv Therapeutics Inc. is Delaware.

What is the principal executive office address for vTv Therapeutics Inc.?

The principal executive office address is 3980 Premier Drive, Suite 310, High Point, NC 27265.

Filing Stats: 619 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-03-14 07:57:57

Key Financial Figures

  • $0.01 — stered Class A common stock, par value $0.01 per share VTVT Nasdaq Capital Market

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. VTV THERAPEUTICS INC. By: /s/ Paul J. Sekhri Name: Paul J. Sekhri Title: President and Chief Executive Officer Dated: March 14, 2024

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.